Literature DB >> 25231819

Complex pattern of interleukin-11-induced inflammation revealed by mathematically modeling the dynamics of C-reactive protein.

Yuri Kheifetz1, Moran Elishmereni, Zvia Agur.   

Abstract

Inflammation underlies many diseases and is an undesired effect of several therapy modalities. Biomathematical modeling can help unravel the complex inflammatory processes and the mechanisms triggering their emergence. We developed a model for induction of C-reactive protein (CRP), a clinically reliable marker of inflammation, by interleukin (IL)-11, an approved cytokine for treatment of chemotherapy-induced thrombocytopenia. Due to paucity of information on the mechanisms underlying inflammation-induced CRP dynamics, our model was developed by systematically evaluating several models for their ability to retrieve variable CRP profiles observed in IL-11-treated breast cancer patients. The preliminary semi-mechanistic models were designed by non-linear mixed-effects modeling, and were evaluated by various performance criteria, which test goodness-of-fit, parsimony and uniqueness. The best-performing model, a robust population model with minimal inter-individual variability, uncovers new aspects of inflammation dynamics. It shows that CRP clearance is a nonlinear self-controlled process, indicating an adaptive anti-inflammatory reaction in humans. The model also reveals a dual IL-11 effect on CRP elevation, whereby the drug has not only a potent immediate influence on CRP incline, but also a long-term influence inducing elevated CRP levels for several months. Consistent with this, model simulations suggest that periodic IL-11 therapy may result in prolonged low-grade (chronic) inflammation post treatment. Future application of the model can therefore help design improved IL-11 regimens with minimized long-term CRP toxicity. Our study illuminates the dynamics of inflammation and its control, and provides a prototype for progressive modeling of complex biological processes in the medical realm and beyond.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25231819     DOI: 10.1007/s10928-014-9383-z

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  61 in total

Review 1.  C-reactive protein and colorectal cancer.

Authors:  D Mazhar; S Ngan
Journal:  QJM       Date:  2006-08

2.  A reduced mathematical model of the acute inflammatory response: I. Derivation of model and analysis of anti-inflammation.

Authors:  Angela Reynolds; Jonathan Rubin; Gilles Clermont; Judy Day; Yoram Vodovotz; G Bard Ermentrout
Journal:  J Theor Biol       Date:  2006-04-03       Impact factor: 2.691

3.  Pharmacokinetics of recombinant human interleukin-11 (rhIL-11) in healthy male subjects.

Authors:  K Aoyama; T Uchida; F Takanuki; T Usui; T Watanabe; S Higuchi; T Toyoki; H Mizoguchi
Journal:  Br J Clin Pharmacol       Date:  1997-06       Impact factor: 4.335

Review 4.  More than a sidekick: the IL-6 family cytokine IL-11 links inflammation to cancer.

Authors:  Tracy Putoczki; Matthias Ernst
Journal:  J Leukoc Biol       Date:  2010-07-07       Impact factor: 4.962

5.  Validation of serum C-reactive protein (CRP) as an independent prognostic factor for disease-free survival in patients with localised renal cell carcinoma (RCC).

Authors:  Michela de Martino; Tobias Klatte; Christoph Seemann; Matthias Waldert; Andrea Haitel; Georg Schatzl; Mesut Remzi; Peter Weibl
Journal:  BJU Int       Date:  2013-03-15       Impact factor: 5.588

6.  Relationship between inflammation and joint destruction in early rheumatoid arthritis: a mathematical description.

Authors:  M C Wick; S Lindblad; L Klareskog; R F Van Vollenhoven
Journal:  Ann Rheum Dis       Date:  2004-07       Impact factor: 19.103

7.  IL-11 regulates autoimmune demyelination.

Authors:  Blake T Gurfein; Yueting Zhang; Carolina B López; Azeb Tadesse Argaw; Andleeb Zameer; Thomas M Moran; Gareth R John
Journal:  J Immunol       Date:  2009-09-04       Impact factor: 5.422

8.  New TPO treatment schedules of increased safety and efficacy: pre-clinical validation of a thrombopoiesis simulation model.

Authors:  Kirill Skomorovski; Hila Harpak; Anton Ianovski; Moshe Vardi; Trudi P Visser; Simone C C Hartong; Huub H D M van Vliet; Gerard Wagemaker; Zvia Agur
Journal:  Br J Haematol       Date:  2003-11       Impact factor: 6.998

9.  Personalising docetaxel and G-CSF schedules in cancer patients by a clinically validated computational model.

Authors:  O Vainas; S Ariad; O Amir; W Mermershtain; V Vainstein; M Kleiman; O Inbar; R Ben-Av; A Mukherjee; S Chan; Z Agur
Journal:  Br J Cancer       Date:  2012-07-19       Impact factor: 7.640

10.  Validation of CRP as prognostic marker for renal cell carcinoma in a large series of patients.

Authors:  Sandra Steffens; Astrid Köhler; Raphael Rudolph; Hendrik Eggers; Christoph Seidel; Martin Janssen; Gerd Wegener; Mark Schrader; Markus A Kuczyk; Andres J Schrader
Journal:  BMC Cancer       Date:  2012-09-08       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.